OncoVantaHealthPrecision Oncology
Back to store
Hyrnuo (sevabertinib)Rx Only

Form

film-coated tablets

Strength

10 mg

Pack

120 tablets

Breast Cancer

Hyrnuo

sevabertinib · 10 mg

Efficacy Gauge · Clinical Signal

Target Engagement92%
Progression-Free Survival78%
Tolerability Profile84%

Mechanism of Action

Sevabertinib is an oral, irreversible HER2 tyrosine-kinase inhibitor that covalently binds the HER2 ATP-binding pocket, blocking receptor autophosphorylation and arresting tumor cell division in HER2-amplified malignancies.

Manufacturer

Bayer

Target Protein

HER2

Delivery

Tablets

Quantity

120 tablets

Critical Safety Information

Hyrnuo is a prescription therapy. It may interact with CYP3A4 inhibitors and hormonal treatments. Do not co-administer with grapefruit. Report pregnancy or nursing status immediately. Requires ongoing hepatic monitoring.

Pricing Tier · Select Quantity

Total

$3,180

All orders require a valid prescription and clinical review before fulfillment. Final pricing confirmed after verification.

Patient Reviews

Write a Review

Share your experience with this therapy.

No reviews yet. Be the first to share your experience.

OncoVantaHealth

A clinical-grade command center for life-extending oncology therapies. Precision access, transparent pricing, and scientifically vetted care.

Rx Only · Prescription Therapies

Affiliated with Princess Margaret Cancer Centre · UHN

Support

This storefront provides access to prescription oncology therapies. All orders require a valid prescription and clinical review. Not a substitute for medical advice.